Skip to main content
OpenTrials
Completed

NCT Number: NCT03563677

Dual Guidance Structure for Evaluation of Patients With Unclear Diagnosis in Centers for Rare Diseases

In people suffering from a rare disease the diagnostic process and the confirmation of a final diagnosis is often ongoing for many years. Factors contributing to delayed diagnosis include the limited knowledge of health care professionals about rare diseases and their symptoms but also a psychiatric or psychosomatic (co-)morbidity obscuring the symptoms of the rare disease. The project ZSE-DUO will evaluate whether a combination of an expert in somatic medicine and a psychiatric/psychosomatic specialist will increase the rate of assured diagnoses in patients approaching a center of rare diseases (primary outcome), accelerate the process until a diagnosis is made, reduce the costs of diagnosing a patient, and lead to a higher satisfaction of patients and health care professionals. Furthermore, the project will evaluate whether the use of psychosomatic screening tools at registration of a patient in a center for rare diseases will help to guide the diagnostic process. Two cohorts of 682 patients each will be sequentially recruited over 9 plus 9 months: the Control group cohort (CG based on somatic expertise) and the Experimental group cohort (EG combined psychosomatic/somatic expertise Included will be persons from the age of at least 12 years presenting with symptoms and signs which are not explained by current diagnoses (as judged by the patient's primary care physician and a specialized physician at the center for rare diseases ZSE evaluating the medical records). Patients will be recruited from 11 German Centers for Rare Diseases associated with University hospitals in the cities of Aachen, Bochum, Frankfurt, Hannover, Magdeburg, Mainz, Münster, Regensburg, Tübingen, Ulm and Würzburg. Recruitment will be supported by a collaboration with the German patient organization representing many rare disease organizations ACHSE e.V. and a collaboration with the insurance companies Techniker Krankenkasse, IKK gesund plus and AOK Hessen who also provide data on costs of care. Data collection and analysis will be coordinated and performed by the Institute for Clinical Epidemiology and Biometry at the University of Würzburg, the Institute for Epidemiology, Social Medicine and Science of Health Care Systems in Hannover, and the Department of Medical Psychology in Hamburg. The project is funded by the Innovationsfond of the Federal Joint Committee in Germany.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Center for Rare Diseases ZESE, University Hospital, Würzburg, Bavaria, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • first contact with the Center for Rare Diseases for unclear diagnosis
  • suspicion of a rare disease but no established diagnosis
  • attending the Center for Rare Diseases as an outpatient
  • written informed consent

Exclusion criteria

  • age <12 years
  • incomplete medical records including summary letters, imaging studies, blood tests etc.
  • pre-diagnosed disease(s) explaining all symptoms

Treatment and study plan

dual expert guidance structure

Other

Two medical experts, one somatic specialist and one psychiatrist/psychosomatic specialist see all medical records and the patients together

Primary outcomes

  1. Diagnoses made

    Time frame: 12 months after signing the consent form

    The number of diagnoses explaining the symptomatology of the patient made during the evaluation process

Secondary outcomes

  1. Time to diagnosis

    Time frame: 12 months after signing the consent form

    The time it takes to make a diagnosis

  2. Patient satisfaction with diagnostic process using ZUF-8

    Time frame: 12 months after signing the consent form

    The patients' satisfaction with the diagnostic process is assessed in the total sample with the questionnaire ZUF-8 (Fragebogen zur Patientenzufriedenheit - patient satisfaction questionnaire) and in a randomly selected subsample of about 40 patients by structured telephone interviews.

  3. Costs of the diagnostic process

    Time frame: up to 12 months after signing the consent from

    estimated costs from first contact with the center for rare diseases until a diagnosis explaining the symptoms has been established

  4. Patients' quality of life using EQ-5D and SF12 (or KIDSCREEN-10 for children)

    Time frame: 12 months after signing the consent from

    Change in the patients' quality of life as assessed with the Quality of life questionnaires EQ-5D from the EuroQoL Group in all patients and Short Form 12 (SF-12) in patients 16 years and older. In patients younger than 16 years, the health-related quality of life questionnaire for children and adolescents KIDSCREEN-10 is used.

  5. Physician satisfaction with new form of care using new questionnaire

    Time frame: 30 months after the project start (end of the intervention period)

    The satisfaction of physicians working in the Centers fro Rare Diseases with the new form of care compared to standard care will be assessed by a newly developed questionnaire administered to all physicians involved in patient care in the 11 centers. For the development of the questionnaire, 3 focus groups of 10 physicians each will be questioned.

  6. Value of screening instruments for psychiatric-psychosomatic (co-)morbidities

    Time frame: 30 months after the project start (end of intervention period)

    Performance of screening tools to identify patients with psychiatric-psychosomatic comorbidities against the judgement of a psychiatrist/psychosomatic expert seeing the patient (intervention group only)

Sponsors and collaborators

Lead sponsor

Wuerzburg University Hospital

Other

Collaborators

  • AOK Hessen
  • Allianz Chronischer Seltener Erkrankungen ACHSE e.V.
  • Goethe University
  • Hannover Medical School
  • IKK gesund plus
  • Otto-von-Guericke University Magdeburg
  • Ruhr University of Bochum
  • St. Josef Hospital Bochum
  • Techniker Krankenkasse
  • University Hospital Regensburg
  • University Hospital Tuebingen
  • University Hospital Ulm
  • University Hospital, Aachen
  • University Medical Center Mainz
  • University of Wuerzburg
  • Universität Münster
  • Universitätsklinikum Hamburg-Eppendorf

Registry information

Official study title

Duale Lotsenstruktur Zur Abklärung Unklarer Diagnosen in Zentren für Seltene Erkrankungen

Acronym: ZSE-DUO

Important dates

Study start
2018
Primary completion
2022
Study completion
2022
First posted
Jun 20, 2018
Registry last updated
Dec 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.